MedStar Authors catalog › Details for: Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.
Normal view MARC view ISBD view

Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.

by Warrow, David J; Lai, Michael M; Patel, Auvni; Berinstein, Daniel M.
Citation: American Journal of Ophthalmology. 159(1):20-30.e1, 2015 Jan..Journal: American journal of ophthalmology.ISSN: 0002-9394.Full author list: Warrow DJ; Lai MM; Patel A; Raevis J; Berinstein DM.UI/PMID: 25220823.Subject(s): Aged | Female | *Fibrinolysin/ad [Administration & Dosage] | *Fibrinolytic Agents/tu [Therapeutic Use] | Humans | Intravitreal Injections | Male | *Peptide Fragments/ad [Administration & Dosage] | *Retinal Diseases/dt [Drug Therapy] | Retrospective Studies | Risk Factors | Tissue Adhesions/dt [Drug Therapy] | Tomography, Optical Coherence | Visual AcuityInstitution(s): MedStar Washington Hospital CenterDepartment(s): OphthalmologyActivity type: Journal Article.Medline article type(s): Journal Article | Research Support, Non-U.S. Gov'tOnline resources: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/j.ajo.2014.09.015 (Click here) Abbreviated citation: Am J Ophthalmol. 159(1):20-30.e1, 2015 Jan.Local Holdings: Available online from MWHC library: 1998 - present, Available in print through MWHC library: 1996 - 2006.Abstract: PURPOSE: To determine treatment outcomes of intravitreal ocriplasmin in symptomatic vitreomacular adhesion.Abstract: DESIGN: Retrospective interventional case series.Abstract: METHODS: setting: Private practice. study population: Thirty-five eyes (35 subjects) with symptomatic vitreomacular adhesion. intervention/observation: Intravitreal ocriplasmin injection from February to November 2013. main outcome measure: Vitreomacular adhesion resolution rate. Secondary endpoints included postinjection visual acuity and rates of outer retinal attenuation and full-thickness macular hole (MH) closure.Abstract: RESULTS: The 35 subjects included were of mean age 69 years, 66% female, and 71% phakic. Eleven subjects (31%) had macular comorbidities. Average adhesion diameter was 571 mum, with mean 7.9 months duration of symptoms. Nine subjects (26%) had epiretinal membrane and 6 (17%) had MH (mean diameter 186 mum). Mean preinjection logarithm of the minimal angle of resolution visual acuity was 0.46, and improved to 0.33 at final follow-up. Fifteen eyes (43%) achieved adhesion release at mean 10 days post injection. One of 6 MH (17%) closed. Transient outer retinal attenuation occurred in 10 of 35 cases (29%), with 8 of 10 (80%) achieving adhesion release. One subject (3%) developed a retinal detachment. Adhesion resolution was more likely in patients with younger age (P = .04), absence of comorbidities (P = .02), small adhesion diameter (P = .005), short adhesion duration (P = .03), and transient outer retinal attenuation (P = .008).Abstract: CONCLUSIONS: Intravitreal ocriplasmin efficacy in the private practice setting, while including patients with macular comorbidities, is similar to that of previous studies. Transient toxicity to the outer retina occurs frequently-typically with adhesion resolution-necessitating careful postinjection spectral-domain optical coherence tomography monitoring.Copyright � 2015 Elsevier Inc. All rights reserved.

Powered by Koha